Association study of the INPP1, 5HTT, BDNF, AP-2β and GSK-3β GENE variants and restrospectively scored response to lithium prophylaxis in bipolar disorder

Neuroscience Letters

Volumn 403, Issue 3, 2006, Pages 288-293

  Michelon, Leandro ^a   Meira Lima, Ivanor ^a   Cordeiro, Quirino ^a   Miguita, Karen ^a   Breen, Gerome ^b   Collier, David ^b   Vallada, Homero ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Mood stabilizer; Pharmacogenetics; Pharmacogenomics; Polymorphism

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; GLYCOGEN SYNTHASE KINASE 3; INOSITOL POLYPHOSPHATE; LITHIUM; TRANSCRIPTION FACTOR IIB;

ADULT; ALLELE; ARTICLE; BIPOLAR DISORDER; DISEASE PREDISPOSITION; DRUG RESPONSE; ETHNOLOGY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; PRIORITY JOURNAL; PROPHYLAXIS; SCORING SYSTEM;

ANTIMANIC AGENTS; BIPOLAR DISORDER; BRAIN-DERIVED NEUROTROPHIC FACTOR; FEMALE; GENE FREQUENCY; GENOTYPE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LITHIUM CARBONATE; MALE; MIDDLE AGED; PHOSPHORIC MONOESTER HYDROLASES; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TRANSCRIPTION FACTOR AP-2;

EID: 33745920543     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2006.05.001     Document Type: Article

References (42)

1. Alda M. Pharmacogenetics of lithium response in bipolar disorder. J. Psychiatry Neurosci. 24 (1999) 154-158
2. American Psychiatric Association (Ed.), Diagnostic and Statistical Manual of Mental Disorders DSM-IV (4th ed.), American Psychiatric Press, Washington, 1994, 886 pp.
3. Bauer M., Alda M., Priller J., Young L.T., and International Group For The Study Of Lithium Treated Patients (IGSLI). Implications of the neuroprotective effects of lithium for the treatment of bipolar and neurodegenerative disorders. Pharmacopsychiatry 36 (2003) 250-254
4. Benedetti F., Serretti A., Pontiggia A., Bernasconi A., Lorenzi C., Colombo C., and Smeraldi E. Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta -50 T/C SNP. Neurosci. Lett. 376 (2005) 51-55
5. Bosetti F., Seemann R., Bell J.M., Zahorchak R., Friedman E., Rapoport S.I., and Manickam P. Analysis of gene expression with cDNA microarrays in rat brain after 7 and 42 days of oral lithium administration. Brain Res. Bull. 15 (2002) 205-209
6. Bratti I.M., Baldessarini R.J., Baethge C., and Tondo L. Pretreatment episode count and response to lithium treatment in manic-depressive illness. Harv. Rev. Psychiatry 11 (2003) 245-256
7. Brunello N., and Tascedda F. Cellular mechanisms and second messengers: relevance to the psychopharmacology of bipolar disorders. Int. J. Neuropsychopharmacol. 6 (2003) 181-189
8. Chen Z.-Y., Patel P.D., Sant G., Meng C.-X., Teng K.K., Hempstead B.L., and Lee F.S. Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. J. Neurosci. 24 (2004) 4401-4411
9. Cho H.J., Meira-Lima I., Cordeiro Q., Michelon L., Sham P., Vallada H., and Collier D.A. Population-based and family-based studies on the serotonin transporter gene polymorphisms and bipolar disorder: a systematic review and meta-analysis. Mol. Psychiatry 10 (2005) 771-781
10. Damberg M., Garpenstrand H., Berggârd C., Asberg M., Hallman J., and Oreland L. The genotype of human transcription factor AP-2b is associated with platelet monoamine oxidase B activity. Neurosci. Lett. 291 (2000) 204-206
11. Damberg M., Ekblom J., Ekblom L., and Ekblom O. Chronic pharmacological treatment with certain antidepressants alters the expression and DNA-binding activity of transcription factor AP-2. Life Sci. 68 (2000) 669-678
12. Duffy A., Turecki G., Grof P., Cavazzoni P., Grof E., Joober R., Ahrens B., Berghofer A., Muller-Oerlinghausen B., Dvorakova M., Libigerova E., Vojtechovsky M., Zvolsky P., Nilsson A., Licht R.W., Rasmussen N.A., Schou M., Vestergaard P., Holzinger A., Schumann C., Thau K., Robertson C., Rouleau G.A., and Alda M. Association and linkage studies of candidate genes involved in GABAergic neurotransmission in lithium-responsive bipolar disorder. J. Psychiatry Neurosci. 25 (2000) 353-358
13. Egan M.F., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S., Bertolino A., Zaitsev E., Gold B., Goldman D., Dean M., Lu B., and Weinberger D.R. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112 (2003) 257-269
14. In: First M.B., Spitzer R.L., Gibbon M., and Williams J.B.W. (Eds). Structured Clinical Interview for DSM-IV Axis I Disorders Clinician Version (SCID-CV) (1997), American Psychiatric Press, Washington 84
15. Ftouhi-Paquin N., Alda M., Grof P., Chretien N., Rouleau G., and Turecki G. Identification of three polymorphisms in the translated region of PLC-γ1 and their investigation in lithium responsive bipolar disorder. Am. J. Med. Genet. (Neuropsychiatric Genetics) 105 (2001) 301-305
16. Fukumoto T., Morinobu S., Okamoto Y., Kagaya A., and Yamawaki S. Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology 158 (2001) 100-106
17. Guindalini C., Howard H., Haddley K., Laranjeira R., Collier D., Ammar N., Craig I., O'Gara C., Bubb V.J., Greenwood T., Kelsoe J., Asherson P., Murray R.M., Castelo A., Quinn J.P., Vallada H., and Breen G. A dopamine transporter gene functional variant associated with cocaine abuse in a Brazilian sample. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 4552-4557
18. Heils A., Teufel A., Petri S., Stober G., Riederer P., Bengel D., and Lesch K.P. Allelic variation of human serotonin transporter gene expression. J. Neurochem. 66 (1996) 2621-3264
19. Jope R.S., and Bijur G.N. Mood stabilizers, glycogen synthase kinase-3beta and cell survival. Mol. Psychiatry 7 (2002) 35-45
20. Kleindienst N., Engel R.R., and Greil W. Psychosocial and demographic factors associated with response to prophylactic lithium: a systematic review for bipolar disorders. Psychol. Med. 35 (2005) 1685-1694
21. Kulhara P., Basu D., Mattoo S.K., Sharan P., and Chopra R. Lithium prophylaxis of recurrent bipolar affective disorder: long-term outcome and its psychosocial correlates. J. Affect Disorders 54 (1999) 87-96
22. Mai L., Jope R.S., and Li X. BDNF-mediated signal transduction is modulated by GSK3beta and mood stabilizing agents. J. Neurochem. 82 (2002) 75-83
23. Mamdani F., Groisman I.J., Alda M., and Turecki G. Pharmacogenetics and bipolar disorder. Pharmacogenomics J. 4 (2004) 161-170
24. Manji H.K., and Chen G. PKC, MAP kinases and the bcl-2 family of proteins as long-term targets for mood stabilizers. Mol. Psychiatry 7 (2002) 46-56
25. Manji H.K., McNamara R., Chen G., and Lenox R.H. Signalling pathways in the brain: cellular transduction of mood stabilization in the treatment of manic-depressive illness. Aust. N.Z. J. Psychiatry 33 (1999) 65-83
26. McKeigue P.M., Carpenter J.R., Parra E.J., and Shriver M.D. Estimation of admixture and detection of linkage in admixed populations by a Bayesian approach: application to African-American populations. Ann. Hum. Genet. 64 (2000) 171-186
27. Miller S.A., Dykes D.D., and Polesky H.F. A single salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16 (1988) 1215
28. Neves-Pereira M., Mundo E., Muglia P., King N., Macciardi F., and Kennedy J.L. The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorder: evidence from a family-based association study. Am. J. Hum. Genet. 71 (2002) 651-655
29. Ott J. Methods of analysis and resources available for genetic trait mapping. J. Hered. 90 (1999) 68-70
30. Parra F.C., Amado R.C., Lambertucci J.R., Rocha J., Antunes C.M., and Pena S.D. Color and genomic in Brazilians. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 177-182
31. Peselow E.D., Fieve R.R., Difglia C., and Sanfilipo M.P. Lithium prophylaxis of bipolar illness. Br. J. Psychiatry 164 (1994) 208-214
32. Picardi M.P., Ardau R., Chillotti C., Deleuze J.F., Mallet J., Meloni R., Oi A., Severino G., Congiu D., Bayorek M., and Del Zompo M. Manic-depressive illness: an association study with inositol polyphosphate 1-phosphatase and serotonin transporter genes. Psychiatr. Genet. 12 (2002) 23-27
33. Russ C., Lovestone S., and Powell J.F. Identification of genomic organisation, sequence variants and analysis of the role of the glycogen synthase kinase 3 beta gene and promoter in late onset Alzheimer's disease. Mol. Psychiatry 6 (2001) 320-324
34. Serretti A., and Artioli P. Predicting response to lithium in mood disorders: role of genetic polymorphisms. Am. J. Pharmacogenomics 3 (2003) 17-30
35. Serretti A., Lilli R., Lorenzi C., Franchini L., DiBella D., Catalano M., and Smeraldi E. Dopamine receptor D2, D4, GABA(A) alpha-1 subunit genes and response to lithium prophylaxis in mood disorders. Psychiatry Res. 87 (1999) 7-19
36. Serretti A., Lilli R., Lorenzi C., Gasperini M., and Smeraldi E. Tryptophan hydroxylase gene and response to lithium prophylaxis in mood disorders. J. Psychiatr. Res. 33 (1999) 371-377
37. Serretti A., Lilli R., Mandelli L., Lorenzi C., and Smeraldi E. Serotonin transporter gene associated with lithium prophylaxis in mood disorders. Pharmacogenomics J. 1 (2001) 71-77
38. Serretti A., Lorenzi C., Lilli R., and Smeraldi E. Serotonin receptor 2A, 2C, 1A genes and response to lithium prophylaxis in mood disorders. J. Psychiatr. Res. 34 (2000) 89-98
39. Sklar P., Gabriel S.B., McInnis M.G., Bennett P., Lim Y.-M., Tsan G., Schaffner S., Kirov G., Jones I., Owen M., Craddock N., DePaulo J.R., and Lander E.S. Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus. Mol. Psychiatry 7 (2002) 570-593
40. Spielman R.S., and Ewens W.J. The TDT and other family-based tests for linkage disequilibrium and association. Am. J. Hum. Genet. 59 (1996) 983-989
41. Steen V.M., Lovlie R., Osher Y., Belmaker R.H., Berle J.O., and Gulbrandsen A.K. The polymorphic inositol polyphostate 1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium responsive manic-depressive illness. Pharmacogenetics 8 (1998) 259-268
42. Turecki G., Grof P., Cavazzoni P., Duffy A., Grof E., Ahrens B., Berghofer A., Muller-Oerlinghausen B., Dvorakova M., Libigerova E., Vojtechovsky M., Zvolsky P., Joober R., Nilsson A., Prochazka H., Licht R.W., Rasmussen N.A., Schou M., Vestergaard P., Holzinger A., Schumann C., Thau K., Rouleau G.A., and Alda M. MAOA: association and linkage studies with lithium responsive bipolar disorder. Psychiatr. Genet. 9 (1999) 13-16